Serum Levels of Interleukin 35 as Risk Markers for Increased Mortality in Lung Cancer with Covid-19

Abstract

Background: Worldwide, lung cancer is still the biggest killer when it comes to cancer, arising from uncontrolled cell division in lung tissues. A homeostatic chemokine with a high degree of conservation, SARS-CoV-2, the culprit responsible for the 2019 new coronavirus disease (COVID-19), has posed a serious threat to worldwide public health. Additionally, COVID-19 infection may predispose persons to hyperglycemia. Hyperglycemia, when combined with other risk factors, may modify immunological and inflammatory responses, predisposing patients to severe COVID-19 infection.

Methods: The materials and methods are a case-control study conducted on 180 participants (aged 45–77): There were 90 patients of lung cancer, and 90 were healthy controls. IL-35 levels were measured using ELISA, along with CBC, cholesterol, triglycerides, and liver enzymes (ALT, AST, ALP).

Results: The average age of all lung cancer patients with COVID-19 was 45-77 years. The patients with lung cancer and Coronavirus had a significantly lower lymphocyte count and platelet count compared with the healthy, but the neutrophil was significantly higher when compared with the same groups. In the severe disease group, the leucocyte count and neutrophil count were significantly higher when compared with moderate disease. D-dimer, ferritin, and alkaline phosphatase were significantly higher, but platelet and albumin were significantly lower when compared with the same groups.

Conclusions: Our results support the idea that COVID-19 should be considered a risk factor for COVID-19 disease progression and prognosis. covid should receive increased care in the event of rapid deterioration. To identify information gaps that necessitate additional research on COVID-19 in  lung cancer